ArticleJournal of applied clinical medical physics2025
Online adaptive MR-guided SBRT versus CT-based planning in pancreatic cancer: A single-center dosimetric comparative study.
Article in Journal of applied clinical medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dosimetric impact of daily MR-guided adaptive radiotherapy across different anatomical sites.Irish journal of medical science · 2026Article
- Online adaptive MR-guided SBRT versus CT-based planning in pancreatic cancer: A single-center dosimetric comparative study.Journal of applied clinical medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic body radiotherapy (SBRT) for pancreatic cancer is limited by the proximity of tumors to gastrointestinal (GI) organs, increasing the risk of toxicity. Magnetic resonance-guided radiotherapy (MRgRT) offers potential advantages through superior soft tissue visualization, real-time tumor tracking, and online adaptive planning. This study aimed to quantitatively compare dosimetric outcomes of pancreatic cancer SBRT using online adaptive MRgRT versus conventional computed tomography-based image-guided radiotherapy (CT-IGRT).
methodsA retrospective dosimetric analysis was conducted on 100 plans from 10 patients with primary (n = 3) or recurrent (n = 7) pancreatic adenocarcinoma treated between July 2021 and December 2022 at UZ Brussel. Treatment included 80 adaptive MRgRT fractions, 10 initial MR plans, and 10 CT-based volumetric-modulated arc therapy (VMAT) plans using an internal target volume (ITV) approach. All patients were treated on the MRIdian system with daily online adaptation and real-time beam gating. Dosimetric endpoints included target coverage, plan quality metrics, and organ-at-risk (OAR) doses. Statistical comparisons were performed using Wilcoxon signed-rank tests.
resultsMRgRT significantly reduced target volumes compared to CT-IGRT (median gross tumor volume (GTV): 40.65 cc vs. 62.56 cc; p = 0.005; median planning target volume (PTV): 64.4 cc vs. 94.4 cc; p = 0.005) and improved dose coverage of both GTV and PTV. Intermediate dose spillage (R50%) was also lower with MRgRT (5.18 vs. 6.56, p = 0.04). MRgRT plans provided superior sparing of critical GI OARs, with median D
conclusionsMR-guided adaptive SBRT demonstrated dosimetric superiority over CT-IGRT in pancreatic cancer, with improved target coverage and enhanced GI OAR sparing. These findings support the use of MRgRT to expand the therapeutic window for safe dose escalation. Prospective studies are warranted to confirm clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.